Vorinostat

Structural formula
General
Non-proprietary name	Vorinostat
other names	N -hydroxy- N ′ -phenyloctanediamide ( IUPAC )
Molecular formula	C 14 H 20 N 2 O 3
External identifiers / databases
EC number	682-505-1
ECHA InfoCard	100.207.822
PubChem	5311
ChemSpider	5120
DrugBank	DB02546
Wikidata	Q905901
Drug information
ATC code	L01 XX38
Drug class	Cytostatic
properties
Molar mass	264.32 g · mol -1
Physical state	firmly
Melting point	159-160.5 ° C
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances danger
H and P phrases	H: 341-360
	P: ?
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Vorinostat (trade name in the USA: Zolinza) is an aromatic chemical compound from the group of hydroxamic acids , used as a drug to be administered orally for histone deacetylase inhibition . It is approved for the treatment of advanced, refractory, cutaneous T-cell lymphoma . Other current clinical studies concern the effects of vorinostat in HIV , colon cancer and other cancers, as well as in combination therapies in solid tumors.

pharmacology

Histones represent the protein component of chromatin . Acetylation and deacetylation of the histones regulate the transcription of the DNA. An inhibition of the histone deacetylase leads to a hyperacetylation of the histones. This can u. a. lead to controlled cell death ( apoptosis ) of the cancer cells .

literature

W. Xu, L. Ngo, G. Perez, M. Dokmanovic, PA Marks: Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. In: Proceedings of the National Academy of Sciences . Volume 103, number 42, October 2006, pp. 15540-15545, doi : 10.1073 / pnas.0607518103 , PMID 17030815 , PMC 1592530 (free full text).
LK Gediya, P. Chopra, P. Purushottamachar, N. Maheshwari, VC Njar: A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. In: Journal of medicinal chemistry. Volume 48, Number 15, July 2005, pp. 5047-5051, doi : 10.1021 / jm058214k , PMID 16033284 .

Web links

With cancer drug against HIV - AIDS experts hope for a cure. At: ntv.de on March 19, 2012

Individual evidence

^ The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals , 14th Edition (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; P. 1728, ISBN 978-0-911910-00-1 .
↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of N-Hydroxy-N-phenyloctanediamide in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on January 13, 2020, is reproduced from a self-classification by the distributor .

[MERCK_Index-1] The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals , 14th Edition (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; P. 1728, ISBN 978-0-911910-00-1 .

[2] Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of N-Hydroxy-N-phenyloctanediamide in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on January 13, 2020, is reproduced from a self-classification by the distributor .